Skip to main content
Journal cover image

A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes.

Publication ,  Journal Article
Roe, MT; Christenson, RH; Ohman, EM; Bahr, R; Fesmire, FM; Storrow, A; Mollod, M; Peacock, WF; Rosenblatt, JA; Yang, H; Fraulo, ES; Gibler, WB ...
Published in: Am Heart J
December 2003

BACKGROUND: The acute benefits of platelet glycoprotein IIb/IIIa inhibitors for non-ST-segment elevation acute coronary syndromes (NSTE ACS) remain unclear. METHODS: In this pilot trial, 311 patients with NSTE ACS were randomly assigned in the emergency department to double-blinded therapy with eptifibatide or placebo for 12 to 24 hours before crossover to open-label eptifibatide. Serial creatine-kinase MB (CK-MB) and quantitative cardiac troponin T levels were collected during the first 24 hours to assess the impact of early platelet glycoprotein IIb/IIIa blockade on infarct size as measured by cardiac markers. RESULTS: Median peak CK-MB (10.3 vs 11.8 ng/mL; P =.71) and peak quantitative cardiac troponin T levels (0.2 vs 0.3 ng/mL; P =.95) were similar between treatment groups, respectively. Median calculated peak CK-MB values (41 vs 40 ng/mL; P =.72) and area under the CK-MB curve measurements (980 vs 764 microg/min/L; P =.68) from curve-fitting analyses that could be performed in 106 of 311 patients were also similar. CONCLUSIONS: In this pilot trial, early administration of eptifibatide in the emergency department did not modulate serologic measurements of infarct size in patients with NSTE ACS.

Duke Scholars

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

December 2003

Volume

146

Issue

6

Start / End Page

993 / 998

Location

United States

Related Subject Headings

  • Troponin T
  • Syndrome
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
  • Pilot Projects
  • Peptides
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Isoenzymes
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Roe, M. T., Christenson, R. H., Ohman, E. M., Bahr, R., Fesmire, F. M., Storrow, A., … Emergency Medicine Cardiac Research and Education Group, . (2003). A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes. Am Heart J, 146(6), 993–998. https://doi.org/10.1016/S0002-8703(03)00517-9
Roe, Matthew T., Robert H. Christenson, E Magnus Ohman, Raymond Bahr, Francis M. Fesmire, Alan Storrow, Michael Mollod, et al. “A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes.Am Heart J 146, no. 6 (December 2003): 993–98. https://doi.org/10.1016/S0002-8703(03)00517-9.
Roe MT, Christenson RH, Ohman EM, Bahr R, Fesmire FM, Storrow A, et al. A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes. Am Heart J. 2003 Dec;146(6):993–8.
Roe, Matthew T., et al. “A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes.Am Heart J, vol. 146, no. 6, Dec. 2003, pp. 993–98. Pubmed, doi:10.1016/S0002-8703(03)00517-9.
Roe MT, Christenson RH, Ohman EM, Bahr R, Fesmire FM, Storrow A, Mollod M, Peacock WF, Rosenblatt JA, Yang H, Fraulo ES, Hoekstra JW, Gibler WB, EARLY Investigators, Emergency Medicine Cardiac Research and Education Group. A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes. Am Heart J. 2003 Dec;146(6):993–998.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

December 2003

Volume

146

Issue

6

Start / End Page

993 / 998

Location

United States

Related Subject Headings

  • Troponin T
  • Syndrome
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
  • Pilot Projects
  • Peptides
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Isoenzymes